15 Small-Cap Stocks Poised to Outperform in 2025

Page 8 of 14

7. Sangamo Therapeutics Inc. (NASDAQ:SGMO)

Shares of Sangamo Therapeutics have been up by 164.71 percent in the past year, reflecting investor optimism, despite booking declines in its five-year performance.

Analysts posted a more bullish outlook for the company, setting a price target of $7 in the latest research last month.

In other news, the company recently terminated a partnership with Pfizer for their hemophilia A gene therapy co-development agreement. Following the termination, Sangamo now regains the rights to develop giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe hemophilia A.

Sangamo said it intends to explore all options to advance the program, including seeking a potential partner to collaborate with.

Page 8 of 14